MOUNTAINSIDE, NJ, Dec 13, 2010 (MARKETWIRE via COMTEX) -- Proteonomix, Inc. (OTCBB: PROT) notes the favorable similarity between technology involved in the Cephalon, Inc. (CEPH) transaction with Australian company Mesoblast Limited. Michael Cohen, the Company's founder and CEO stated, "We applaud the transaction between Cephalon and Mesoblast and take this opportunity to note that our StromaCel(R) bone marrow derived stem cell technology attacks similar medical problems with a different approach." (Transaction Hyperlink)
Mr. Cohen continued, "Our StromaCel(R) technology is also designed to treat damage to cardiac tissue caused by myocardial infarction (MI) and we are actively seeking funding to open clinics worldwide to treat MI patients. This technology was developed in conjunction with the University of Miami where bone marrow derived stem cells are undergoing Phase I trials. We are seeking joint venture partners to give effect to this strategy."
About Proteonomix, Inc. and subsidiaries:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit www.proteonomix.com, www.proteoderm.com, www.otcqb.com and www.sec.gov.
Forward-looking statments:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. |
